Nanosuspensions as a promising approach to enhance bioavailability of poorly soluble drugs : An update by Azimullah, Stanekzai et al.
 Azimullah et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2019; 9(2):574-582     
ISSN: 2250-1177                                                                                  [574]                                                                                 CODEN (USA): JDDTAO 
Available online on 20.03.2019 at http://jddtonline.info 
Journal of Drug Delivery and Therapeutics 
Open Access to Pharmaceutical and Medical Research 
© 2011-18, publisher and licensee JDDT, This is an Open Access article which permits unrestricted 
non-commercial use, provided the original work is properly cited 
Open  Access                                                                                                                                                             Review Article 
Nanosuspensions as a promising approach to enhance bioavailability of 
poorly soluble drugs : An update 
Stanekzai Azimullah *, Vikrant1, Sudhakar CK1, Kumar Pankaj1, Patil Akshay2, Md. Rageeb Md. Usman2, 
Mohammed Zuber Shaikh Usman3, Bharat V. Jain2 
* Research Scholar, Lovely Institute of Technology (Pharmacy) School of Pharmaceutical Sciences Lovely Professional University Phagwara, 
Punjab and Lecturer at Kabul University, Faculty of Pharmacy, Deportment of Pharmaceutics.  
1 Lovely Institute of Technology (Pharmacy) School of Pharmaceutical Sciences Lovely Professional University Phagwara, Punjab.  
2 Smt. S. S. Patil College of Pharmacy, Chopda, Maharashtra, India 
3 RFNS, Senior Science College, Akkalkuwa, District Nandurbar, Maharashtra, India 
 
ABSTRACT 
Solubility is a vital factor for devloping drug delivery systems for poorly water soluble drugs. Several conventional approac hes for enhancement 
of solubility have limited applicability, especially when the drugs are poorly water soluble. Nanosuspension technology can be used to enhance 
the solubilty, stability as well as the bioavailability of poorly water soluble drugs. Nanosuspensions are biphasic systems comperising of pure 
drug particles dispersed in an aqueous vehicle, stabilized by surfac active agents. Fabrication of nanosuspension is simple and more 
advantageous than other approaches. Techniques like high-pressure homogenization, wet milling, emulsification, solvent evaporation, bottom up 
technology and top down technology have been applicable in the fabrication of nanosuspensions. Nanosuspension delivery is possible by several 
routes, such as oral, pulmonary, parenteral and ocular routes. Nanosuspension not only solves solubility and bioavailability issue, but improve 
drug safety and efficacy. In this context, we reviewed the current techniques used to develop nanosuspensions and their recents studies 
application in drug delivery system. 
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INTRODUCTION 
In recent years, more than 40% of the new chemical moities 
being generated by drug discovery projets are lipophilic in 
nature or poorly soluble in water. Developing poorly water 
soluble drug has always been a challenging issue confronted 
by the pharmaceutical researchers. To tackle this issue, nano 
sized formulation of these compunds can be implemented to 
all drug compounds belonging to biopharmaceutical 
classification system (BCS) classes II and IV to increase their 
solubility and attaining higher bioavability. Micronization is 
used for class II drugs of (BCS), i.e. drugs having a good 
permeability and poor solubility 1,2. 
Nanosuspension is a colloidal formulation of very small 
particles (nanosized) of drug in which stabilized by surface 
active agents. The termNanosuspension was derived from 
two words nano and suspension. Nano is related to very 
small (nano range) and suspension is biphasic dosage form 
which is the combination of two phases, namely dispersed 
phase and another one is dispersion medium. Generally, 
nanosuspensions are mainly used to increase 
physicochemical properties as well as safety and efficacy of 
drugs which have low solubility3. 
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ADVANTAGES AND DISADVANTAGES OF NANOSUSPENSIONS4 
 
 
Figure 1: Advantages and Disadvantages of Nanosuspensions 
 
FABRICATION TECHNIQUES OF NANOSUSPENSIONS 
In current scenario, Bottom-up technology and Top-down 
technology are two approaches are used for preparation of 
nanosuspensions. Normally, micronisation technique is most 
probably used for preparation of nanosuspensions and it is 
carried out by jet or media milling. (Muller and Peters et al, 
1995).This method has few limitations such as it enhances 
only dissolution profile of drug but lacks saturation 
solubility. Thus, researchers are finding some alternative 
techniques to preapare nanosuspensions. Further some 
techniques are described with their advantages and 
disadvantages 5,6,7. 
1. Bottom upTechnology  
As the name suggests, this approach starts from the bottom 
i.e start from molecular level and lastly goes to molecular 
association for the formulation of small solid particles. This 
means it is novel precipitation technique in which the 
solvent quantity should be reduced 8. 
 
 
Figure 2: Advantages and Disadvantages of Bottom up Technology 
2. Top down Technology 
Top down approaches involves techniques like Grinding 
(media milling), High pressure homogenization, Nanopure, 
Combined precipitation and homoginisation (nanoedge), 
Nanojet Technology, Emulsification-Solvent Evaporation 
techniques, Hydrosol method, Supercritical Fluid Method, 
Precipitation technique, Dry-co-grinding9. 
2.1 Grinding Technique (mediamilling) 
In this technique, nanosuspension is formed by reducing the 
Disadvantages of Bottom up 
Technology 
 
Advantages of Bottom up 
Technology 
 
Lost Effective Equipment Used  
Enhance Saturation Solubility 
Solvent must be Miscible with 
Non-Solvent 
Increase the Production Cost 
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particles size by the help of pearl and media mills. This 
milling equipment is mainly consists of shaft, milling cabinet, 
and recirculation cabinet. For example, the planetary ball 
mill can reduce the particle size up to 0.1µm. This approach 
is very simple, cost effective and can be possible to scale up. 
However, contamination can be occur during this technique, 
as using milling for longer duration increses germ growth in 
acquos phase. 
2.3 High Pressure Homogenization  
This approach is mainly used for those drugs which show 
low solubility.This strategy includes constraining an course 
suspension, which contains drug and stabilizers through a 
valve with a little hole under pressure 10.In this course, 
suspension is employed through a small area with high 
pressure up to 1500 bar and the result in enhance the 
dynamic pressure with concurrent decrease in the static 
pressure, which decreases the water’s boiling point to 
normal (room) temperature. Thus, at the normal (room) 
temperature water will start boil and create gas bubbles. 
When suspension leaves the gap or area and the pressure 
returns to the atmospheric level, the gas globules crash. This 
process is called as cavitation. The combined forces of 
cavitation, high shear, and collisions lead to fracture of the 
drug microparticles into nanosized particles 11.Number of 
homogenization cycles, homogenization pressure, hardness 
of drugs, and temperature (when thermosensitive drugs are 
processed) are factors that influence the physical 
characteristics (such as particle size) of resulting 
nanosuspensions. Metal contamination because of the 
erosion is less pronounced in this technique than in media 
milling. This technique is also a safe technique for producing 
nanosuspensions. Less than 1 ppm metal contaminations 
were detected under processing condition of 20 cycles and 
pressure of 1500 bar 11,12. The major drawback of this 
method is the need for pretreatment to obtain microparticles 
before starting the homogenization process and the more 
cycles of homogenization13. For various purposes such 
asdispersing drugnanocrystals in low molecular weight PEG 
or in oil, liquid nanosuspensions are dispersed in 
nonaqueous media or media with reduced water content. As 
the low vapour pressure and high boiling point of oily fatty 
acids and oils, the drop in pressure is not sufficient for 
cavitation, thus the latter is not a determining factor in this 
process. To compensate for insufficient drop in pressure, the 
nanopure processis directed at low temperature which is 
often referred to as ―deep- freeze‖ method. Conducting the 
process at 0∘C or even less than 0∘C (freezing point) 
produces results comparable to those achieved using 
dissocubes 14. 
Types of Pressure Homogenization 
2.3.1 Homogenization in Non-Aqueous Media(Nanopure) 
This is another type of preparation technique of 
nanosuspension which involves homogenization in water 
mixtures or water free media and is prepared for the 
thermolabile compound. Nanopure is also called as deep 
freezing because homonigenation of drug suspension is 
carried out in non aqeuous media at 00C temprature i.e. the 
drug suspensions in the non-aqueous media were 
homogenized at 0°C or even belowthe freezing point 
andhence are called ―deep freezehomogenization 2. 
2.3.2 Combined Precipitation & Homogenization 
(Nanoedge) 
As the name indicate both precipitation and homogenization 
are carried out at same time. Combined precipitation is also 
called as nanoedge in which drug mixed in an organic solvent 
and then the solution is also mixed with a miscible anti-
solvent for precipitation. Solubility is low in case of water-
solvent mixture and drug precipitates. Precipitation has also 
been coupled with high shear processing. Principles of 
Nanoedge is the similar as precipitation and homogenization. 
This technique make particle size in nano range and give 
better stability in a very short time15. 
2.3.3 Nanojet Technology 
Nanojet is mostly used technology, in which high pressure of 
force is applied to passes the suspension which is separated 
into at least two sections and that are impact with each other 
due of high shear forces produced all through the process it 
marks to reduce of particle size 16. 
 
Figure 3 : Advantages and Disadvantages of 
Nanojet Technology 
3 Emulsification-Solvent Evaporation Techniques 
By emulsification technique, nanosuspension is prepared by 
a solution of drug followed and on the other handliquid that 
is present in non-solvent for drug, then solvent will 
evaporate and results in precipitation of the nanosize of the 
drug 15. 
4 HydrosolTechnique 
It is same as like emulsification solvent evaporation 
approach. The difference is that in which drug solvent is 
totally miscible in drug anti- solvent. High shear forces can 
face the challenges like ostwald ripening and crystal growth. 
It ensures that, the precipitate which is remaining is smaller 
in size 17. 
5. Supercritical Fluid Method  
There are several techniques which are used for the 
preparation of various formulations like solvent evaporation, 
solvent diffusion, and organic phase separation but these 
methods are hazardous to health as well as environment. So 
facing this challenge, researchers investigated supercritical 
technology which is eco-friendly. These techniques like 
supercritical anti solvent, precipitation with compressed 
antisolvent process (PCS), and rapid expansion supercritical 
solution (RESS). In this process, liquid solvent should be 
used (methanol), because solute is not soluble in 
supercritical fluid so liquid solvent can play a vital role and 
micronized the solute particles, then nanoparticles are 
formed. Dexamethasone phosphate drug nanoparticles and 
Griseofulvin were prepared by this technique.Evaporation of 
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extracted solvent, diffusion of solvent and separation of 
organic phase are generally used in preparation of 
conventional methods18. 
 
Figure 4: Super Critical Fluid technique 18 
5 Precipitation Technique  
This process is carried out by precipitation. In this drug 
dissolved in solvent(organic) which is water soluble to make 
surfactant solution after some time drug will show low 
solubility and result in precipitation on the hand, 
homogenization with pressure is also helpful here,due to 
high pressure production of precipitation will enhance and 
reduce the particle size, which result in higher bioavailability 
and solubility 19. 
6 Dry-co-Grinding 
As the name indicates, grinding is done in this technique 
which helps to improve the surface polarity of drugs. This 
method is mostly used due to simple and cheap and without 
using any organic solvent. Properties such as physiochemical 
and dissolution of low (poor) water soluble drugs can be 
enhanced by co-grinding 20. 
 
 
CRITERIA FOR SELECTION OF DRUG (NANOSUSPENSIONS)21 
 
Figure 5: Selection Criteria for Nanosuspension21 
 
CHARACTERIZATION OF NANOSUSPENSIONS 
Characterization of nanosuspensions is done by various 
methods with different parameters like size of particles, 
particle size distribution and also zeta potential, because 
these parameters are mainly affect on safety, efficacy and 
stability of formulation. Dissolution profiles are also affected 
due to solid state of nanoparticles. Thus, the characterization 
of nanosuspension can play a very crucial role in focussing in 
vitro and in vivo performance of nano drug delivery. In vivo 
pharmacokinetic and therapeutic effect of this formulation is 
mainly depend on particles size, size distribution, the charge 
on particle and also the crystalline nature of particles. 
Particle Size 
Particle size and polydispersity index is one the most crucial 
parameters of nanosuspensions. The size of particles 
determines the various characteristics of nanosuspensions11 
 The rate and extent of drug(bioavailability) 
 Physicalstability 
 Dissolutionrate 
 Drug saturationsolubility 
The Noyes and Whitney equation showed, when the particles 
size reduces, the surface area of the particles, solubility and 
dissolution rate of drug will increase 22,23. 
Photon Correlation Spectroscopy (PCS) 
This technique (PCS) is widely used to measure the particle 
size and also called as dynamic light scattering spectroscopy. 
PCS is capable to accurate measurements of particle sizes in 
range of 3 nm to 3 𝜇m. However, this technique is not 
accurate when particles size is above 3 𝜇m11,24. In this 
technique, the brownian motion (movement in random 
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direction) of particles is measured as a function of time. 
Laser Diffraction (LD) is typically used to measure particle 
size range of 0.05–80 𝜇m up to 2000 𝜇m. This technique can 
also be used to detect and quantify particle size ranges 
during the production procedure, other techniques routinely 
used for measuring particle size are optical and electron 
microscopy. Scanning Electron Microscopy (SEM) 25,26. 
Atomic ForceMicroscope (AFM) 27and Transmission Electron 
Microscopy (TEM)28 are also routinely used to characterize 
nanoparticles size and morphology. Furthermore, the 
Coulter Counter analysis can be used to determine the 
absolute number of particles per unit volume for different 
particle sizes.Other techniques such as Nanoparticle 
Tracking Analysis (NTA)29 and Flow Field Flow Fractionation 
(FIFFF) are example of size analyses of nanoparticles30. 
Particle Morphology and Crystalline State  
The high energy amorphous form of drugs is 
thermodynamically unstable and changes during storage. 
The amorphous form is preferred due to superior dissolution 
characteristics and consequently higher bioavailability of the 
drug31.Before formulating thenanosuspensionthemajorthing 
isthetransformation of amorphous to the crystalline state. In 
order to investigate amorphous and crystalline fractions X-
ray powder diffraction is used. XRPD is sometimes 
considered to be the most appropriate method for evaluating 
drug with crystalline structure, since each crystal has a 
specific diffraction pattern 32.However, it should be taken 
into consideration that there is a slight difference in the 
crystal structure of the same drug as observed by Tian, who 
studied the crystalline forms of carbamazepine33. Terahertz 
spectroscopy is a relatively new analytical method used to 
evaluate crystalline form of drugs where each crystalline 
polymorph form exhibits specific terahertz absorption 
spectrum34,35. Differential Scanning Calorimetry (DSC) is 
another commonly used technique for determining 
crystalline and amorphous fractions. It measures the 
temperatures and heat flows associated with the transition 
in drugs from crystalline to amorphous state as a function of 
time and temperature in a controlled atmosphere. DSC can 
also be used in conjunction with XRPD36,37. 
Particle Charge (ZetaPotential) 
The main role of particle size in nanosuspension is vital to 
ensure stability of nanosuspension. The electric charge on a 
particle surface provides electrostatic repulsion between the 
nanoparticlesand prevents particles from aggregation and 
precipitation, it provides an illustration of the electric double 
layer around a charged particle. The double layer consists of 
a stern layer and a diffusion layer of opposite ions. The 
electric potential at the shear plane is known as the zeta 
potential38. It is considered that a minimum zeta potential of 
30mV is required to ensure pure electrostatic stabilisation. 
When electrostatic stabilisation is combined with steric 
stabilisation (by using appropriate polymers), zeta potential 
of 20mV could be sufficient to prevent drug particles from 
aggregation and precipitation. Steric stabilisation is defined 
as stabilisation caused by the adsorbed and hydrated 
polymer layers on the dispersed particle39. Particles charge 
is typically determined by measuring electrophoretic 
mobility upon application of an electric field which is then 
converted to zeta potential by using the Helmholtz-
Smoluchowski equation 40.The zeta potential can also be 
measured by applying an ultrasound wave which induces 
and called electroacoustic phenomena 41. 
Stability 
Reduction in particle size results in increased surface energy 
due to the greater number of unstable surface atoms and 
molecules. Therefore, the use of stabilisers is often necessary 
to avoid the cluster making of particle and reduce the 
chances for Ostwald ripening 42. Mixture of surfactants and 
polymers has been found to be beneficial for long-term 
stabilisation of nanosuspensions 43,44,45. Polymeric materials 
and surfactants act as an ionic barricade(barrier). 
Surfactants can increase the electrostatic repulsion and 
improve particle stability by altering the zeta potential46. 
Precipitation of particles is another phenomenon that should 
be taken into account when considering stability of 
nanosuspensions. According to Stoke’s law, reducing the size 
of particle and decresing the density difference of solid 
phase, which result an increasing the medium’s velocity and 
decrease the precipitation velocity. 
𝑉= 2𝑟2 (𝜌1− 𝜌2) (9𝜂) 
Where𝑉is the precipitation velocity, 𝑟is the particle size, 𝜌1 
is themass density of particles, 𝜌2 is the mass density of fluid 
and 𝜂is the viscosity of the medium. The stability of 
nanosuspension system can also be increased by increasing 
the uniformity of particle sizes by using centrifugation or 
other techniques to remove larger particles 47. 
Common Stabilizer Which are Used in Nanosuspension 
 
Figure 6: Common Stabilizer Used in Nanosuspension42 
FORMULATION CONSIDERATION OF 
NANOSUSPENSION 
The preparation of Nanosuspension involves the following 
agents : 
 Stabilizer 
 Organicsolvents 
 Surfactant 
 Co-surfactant 
 Otheradditives 
Stabilizer 
In the absence of stabilizer surface energy of nano-sized 
particles are too high it can induce agglomeration or 
aggregation of the drug crystals. In order to yield a physically 
stable formulation, stabilizers are added which makes the 
drug particles thoroughly wet and prevents Ostwald’s 
ripening and agglomeration of nanosuspension by providing 
steric or ionic barriers. Physical stability and in vivo 
behavior of nanosuspensions depends upon the type and 
amount ofstabilizers added. In order to obtain a stable 
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nanosuspension a mixture of stabilizers are required. 
Polysorbate (Tween/Span series), povidone, cellulosic, 
poloxamers, and lecithin are some commonly used as 
stabilizers in the formulation of nanosuspensions 8. 
Organic Solvents 
Toxicity potential and the ease of their removal from 
formulation are the two important factors which decide the 
acceptability of organic solvents in the pharmaceutical area 
during the formulation of nanosuspension by using emulsion 
or microemulsion as templates. Ethanol and isopropanol are 
water miscible solvent, whereas ethyl acetate, ethyl formate, 
butyl lactate, triacetin, propylene carbonate and benzyl 
alcohol are partially water-miscible, less hazardous and 
pharmaceutically acceptable 23. 
Surfactants 
For improving the dispersion in a formulation surfactants 
are incorporated which perform their action as wetting or 
deflocculating reducing the interfacial tension. Being of 
surfactant in the formulation, reduces the interfacial tension 
18. 
Co-Surfactants 
The influence of cosolvent sould be monitored for selected 
nanosuspension composition, which depends on various 
factors like uptake of the internal phase and drug loading 8. 
After going through the literature it describes certain co- 
surfactants for various stabilizers can be safely used in the 
formulation of microemulsion, co-surfactant such as salts 
(dipotassium glycerrhizinate) can be safely used with 
stabilizers like transcutol, glycofurol, ethanol, and 
isopropanol 48. 
OtherAdditives 
Different type of additives are used in the formulation of 
nanosuspensions such as, osmogent, cryoprotectant, polyols, 
buffers and salts which depends upon either the route of 
administeration or properties of the drug moiety23. 
APPLICATIONS OF NANOSUSPENSION 
 
Figure 7: Applications of Nanosuspension 
ORAL DRUG DELIVERY 
In the conventional dosage form (i.e oral drug 
administration) there are number of problem such as 
solubility is poor, inadequate dissolution and does not have 
sufficient efficacy. To overcome these problem oral 
nanosuspension is used, particle size should be very small 
and large surface area as compare to conventional which 
help to increase the bioavalibility and solubility of poorly 
soluble drugs(BCS class-II).Advantages of Nanosuspension 
like high drug loading, enhanced solubility, enhanced 
stability (physical and chemical) and enhanced 
bioavailability. With the help of simple manufacturing 
techniques Nanosuspension can be easily incorporated in to 
numerous dosage forms such as tablets, capsules49.Recently, 
Jeong et al developed a new celecoxib (CXB)- loaded 
nanosuspensions, various nanosuspensions were set up with 
different polymers and surfactants utilizing a wet media 
milling methods, therefore determined the particle size. The 
pharmacokinetic results of prepared formulation are 
compared with powder form of same drug. The 
nanosuspension under the appropriate conditions showed 
the particle size 190 nm, which is increas physical stability (8 
week). This Nanosuspension showed higher plasma 
concentrarion and AUC rate which is compared with powder 
form of conventional product. Therefore nanosuspension 
form of CXB- loaded is increase stability and oral 
bioavailability50. 
PARENERTAL DRUG DELIVERY 
In this day and age, number of methods are available to 
incerase solubility such as solubilization, vesicular system, 
salt formation, cyclodextrin complexation, but these method 
have many problemlike cost of manufacturing process, 
acceptability of parentaral and solubilization capacity, 
therefore nanosuspension technology is used to solve above 
problems. It also help to enhance the efficacy of drugs by 
parental route. Paclitaxel nanosuspension play an important 
role to control or reduce the risk of median tumor burden 4. 
Wang and his co-workers devlopedEtoposide loaded on 
bovine serum albumin nanosuspension by high pressure 
homogenization technique. The partical size and drug 
loading was attended 182,3 nm and 86.49% respectively. 
The in vitro release profile showed sustained release 
properties of etoposide. Hence after studies the tissue 
distribution showed increased concentration and AUC of 
etoposide in liver, spleen and lung but reduced in kideny and 
hearth when campared with injection form of same drug 
51.Tain et al fabricatedp-terphenyl derivative (H2) by 
combining microfluidization and precipitation techniques 
which is formed dry powder by lyophilization method. The 
results of prapared nanosuspension showed 201.7±5.87nm 
particle size with increased the solubility of drug 
(1.46ug/ml) and accelerated dissolution profile 52. 
TARGETED DRUG DELIVERY 
Nanosuspensions can play a very crucial role in targeting a 
particular organ which is affected by any disease or disorder. 
It can also easily change the in vivo behaviour of stabilizer. 
By phagocytic system drug will be engulfed and it is 
responsible for targeting a specific site. Various targeting 
formulation are available such as antifungal, antimicrobial, 
antileishmanial and etc48. AbraxaneTM established a clinical 
standard of paclitaxel which is approved by FDA. Paclitaxel is 
used for treatment of cancer. Yin et al devloped Paclitaxel 
loaded nanosuspension based on human serum albumin 
with poly ethylene glycole (PEG) to optimize 
pharmakokinetics, safety and in vitro biodistribution (PTX-
PEG-HSA). Result of in vivo pharmacokinetics showed 
prolonged plasma circulation 53. Hong and co-workers 
prepared FA-modified ACGs nanosuspensions. Annonaceous 
acetogenins are a biggest family of fatty acid which is derived 
from natural products and related to Annonaceae species, It 
showes anticancer and biological activity. The poorly 
solubility and toxicity restrict their clinicaly application. 
Therfore, modified β-cyclodextrin with folic acid then mixed 
with soybean lecithin to prepare FA-modified ACGs nano-
suspensions. The prepared nanosuspension with 199.5 nm 
average particle size and 57.59% loaded capacity and 
showed within 142 hours sustained release. Hence in vivo 
studies showed enhance cytotoxicity and less toxicity in 4T1 
 Azimullah et al                                                                                                       Journal of Drug Delivery & Therapeutics. 2019; 9(2):574-582     
ISSN: 2250-1177                                                                                  [580]                                                                                 CODEN (USA): JDDTAO 
tumor bearing mices 54. 
OCULAR DRUG DELIVERY 
Nanosuspension is also used for ocular drug delivery to 
sustained the release of drug. Liang and Binner formulated 
cloricromene nanosuspension for ophthalmic (ocular) 
delivery using Eudragit. This work showed higher 
availability of drug in aqueous humor of rabbit eye. Thus, 
Various formulation of Nanosuspension offers a favorable 
tissues for enhancing the bioavailability as well as shelf life 
of drug after ophthalmic application 41.For the treatment of 
ocular disease several advance techniques and various drug 
delivery systemhave been suggested. The importent factors 
which are effect in the success of ocular therapy such as 
development of safe, effective, economic and non-invasive 
new drug delivery systems. These speciale non-
invasive ocular delivery systems are targeted drug 
delivery to the ocular tissues by reducing doses and toxicity 
which arecampared with the conventional formulations. 
Non-invasive systems are prapared with encompassing 
biodegradability, biocompatibility, mucoadhesion, solubility 
and permeability enhancement ingredients55.In addition, 
nanosuspension of triamcinolone acetonide showed 
significant potential such as increase loading capacity, 
release profile and solubility properties. The size of 
nanosuspenstion is suitable for topical ocular drug delivery 
system 56. The studies done by Ambhore et al showed the 
drug is formulated with surfactant and polymer its effect on 
particle size and drug release. Sparfloxacin prepared with 
HPMC and chitosan by solvent diffusion technique which is 
followed by probe sonication. The prepared nanosuspention 
after characterizetion showed 300 to 500 nm average 
particle size, suitable shape, zeta potential and drug release 
profile 57. 
PULMONARY DRUG DELIVERY 
For pulmonary delivery, mechanical or ultrasonic nebulizers 
are the technique which is, nanosuspensions are nebulised. 
All the aerosol droplets contain drug nanoparticles due to 
the presence of small particles. There are various drugs 
which are successfully tried with pulmonary route such as 
budesonide, p53 gene, ibuprofen, nifesipine, and ketotifen 
etc 58.Coenzyme Q10 is an antioxidant substance which is 
indicated as a dietary supplement and proposed as adjuvant 
in the management of cardiovascular disorders and tumor 
for its protective and immunostimulating activities. CoQ10 
nanosuspension designed and administreted to the lungs by 
nebulization. CoQ10 is stabilized by surfactants, such as 
lecithin, PEG32 stearate and vitamin-E TPGS. Particle size 
range of nanosuspension of CoQ10is 35-60 nm, the smallest 
particles size allowed to delivered the drug to the lungs 59. 
TRANSDERMAL DRUG DELIVERY 
Flurbiprofen (FB) isone of the non-steroidal anti-
inflammatory drugs (NSAIDs) it is low water soluble.  
Nanonization is a technique which is converting the drug 
particle in to nano size. Recently, design of experiment (DoE) 
approaches used to develop novel formulations 
of nanosuspensions. Plantacare is as stabilizer using in DoE 
experiment approaches to evaluate the critical formulation 
attributes (CFAs) and critical process parameters (CPPs). For 
dependent variable particle size, particle size distribution 
and zeta potential values were selected while FB%, FB: PL 
and homogenization cycles were independent variables. The 
solubility study of nanosuspensions comparison with the 
coarse powder and physical mixture. The in vitro permeation 
of FB nanosuspension andsolution were determined by 
dialysis bag membrane and rat skin. The particle size (665 
nm-700nm), polydispersity index (0.200-0.300) and zeta 
potential values (-30 mV) were found. FB nanosuspension 
observed with spherical shape and crystalline stracture. The 
solubility of FB was 5.3 fold increased in nanosuspension 
formulation and permeability of FB formulation was higher 
than FB solution in rat skin. Therfore DoE design is a useful 
design to prepare FB nanosuspensions, result is to improve 
water solubility and permeability of skin of BCS Class II 
drugs 60.The slow permeation of many drugs across the skin 
layer is the main disadvantages of transdemal route. There 
are several techniques to cross the skin barrire, such as 
penetration enhancers in topical formulation for example 
diethylene glycol monoethyl ether included in new 
declofinac. The in vitro permeation studies performed by 
Pireddu et al reported nanonizing is as a main factor for 
dermal permeation of topical diclofenac formulation. 
Nanosuspension of diclofenac with diethylene glycol 
monoethyl ether increase the skin permeation of drug across 
the skin 61. 
CONCLUSION 
Initially, nanosuspension technology came to solve problem 
of solubility of poorly soluble drugs. As information was 
attained by applications, nanosuspension solved poor 
solubility and bioavailability problem of hydrophobic 
drugs.Fabrication methods like media milling and high 
pressure homogenizer are utilized for large scale fabrication 
of Nanosuspensions. Nanosuspensions can be administered 
via parenteral, oral, pulmonary, ocular and topical routes. 
This is a major advantage of nanosuspension technology to 
obatin final drug formulation in various forms with patient 
complience.Since nanotechology is simple, cost-effective and 
devloped in a lab scale. Nanosuspensions canincrease 
dissolution velocity and saturation solubility several poor 
bioavailability drugs. Any devloped drug delivery system 
requires safety, efficiency and stability. Moreover, the safety 
and efficiency depended on the stability in some cases. A 
good stability of a formulation is a warranty for a reliable 
safety and efficiency. Therefore, the stability issue of 
nanosuspensions in drug delivery is a very important and 
critical aspect of this technology.  Although, nanosuspensions 
technology has been studied tremendously in laboratory 
scale, its application on pharmaceutics industrial is still 
restrained. The stability issue of nanosuspensions has been 
highlighted as major problem for this.According to our 
notion, upcoming era will emerge in which soluble drugs will 
be intentionally converted to insoluble complexes to take 
advantage of the benefits conferred by nanosuspension drug 
delivery. 
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